Your browser doesn't support javascript.
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
Maeda, Ryota; Fujita, Junso; Konishi, Yoshinobu; Kazuma, Yasuhiro; Yamazaki, Hiroyuki; Anzai, Itsuki; Watanabe, Tokiko; Yamaguchi, Keishi; Kasai, Kazuki; Nagata, Kayoko; Yamaoka, Yutaro; Miyakawa, Kei; Ryo, Akihide; Shirakawa, Kotaro; Sato, Kei; Makino, Fumiaki; Matsuura, Yoshiharu; Inoue, Tsuyoshi; Imura, Akihiro; Namba, Keiichi; Takaori-Kondo, Akifumi.
  • Maeda R; Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan. maeda@cognano.co.jp.
  • Fujita J; COGNANO Inc., Kyoto, 601-1255, Japan. maeda@cognano.co.jp.
  • Konishi Y; Graduate School of Frontier Biosciences, Osaka University, Osaka, 565-0871, Japan.
  • Kazuma Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
  • Yamazaki H; Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
  • Anzai I; Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
  • Watanabe T; COGNANO Inc., Kyoto, 601-1255, Japan.
  • Yamaguchi K; Shizuoka City Shizuoka Hospital, Shizuoka, 420-8630, Japan.
  • Kasai K; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
  • Nagata K; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
  • Yamaoka Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
  • Miyakawa K; COGNANO Inc., Kyoto, 601-1255, Japan.
  • Ryo A; Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
  • Shirakawa K; Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
  • Sato K; Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
  • Makino F; Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
  • Matsuura Y; Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
  • Inoue T; Division of System Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Imura A; Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
  • Namba K; CREST, Japan Science and Technology Agency, Saitama, 332-0012, Japan.
  • Takaori-Kondo A; Graduate School of Frontier Biosciences, Osaka University, Osaka, 565-0871, Japan.
Commun Biol ; 5(1): 669, 2022 07 06.
Article in English | MEDLINE | ID: covidwho-1921727
ABSTRACT
We are amid the historic coronavirus infectious disease 2019 (COVID-19) pandemic. Imbalances in the accessibility of vaccines, medicines, and diagnostics among countries, regions, and populations, and those in war crises, have been problematic. Nanobodies are small, stable, customizable, and inexpensive to produce. Herein, we present a panel of nanobodies that can detect the spike proteins of five SARS-CoV-2 variants of concern (VOCs) including Omicron. Here we show via ELISA, lateral flow, kinetic, flow cytometric, microscopy, and Western blotting assays that our nanobodies can quantify the spike variants. This panel of nanobodies broadly neutralizes viral infection caused by pseudotyped and authentic SARS-CoV-2 VOCs. Structural analyses show that the P86 clone targets epitopes that are conserved yet unclassified on the receptor-binding domain (RBD) and contacts the N-terminal domain (NTD). Human antibodies rarely access both regions; consequently, the clone buries hidden crevasses of SARS-CoV-2 spike proteins that go undetected by conventional antibodies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Single-Domain Antibodies / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03630-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Single-Domain Antibodies / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03630-3